Evidence map›Paper›PMID 42560632›Full record

ArticleInfectious diseases and therapy2026

Clinical Research on Microecological Landscape for Infection Risk Stratification in Newly Diagnosed Patients with Hematological Conditions.

Miaoxin Peng, Yueyi Xu, Xuefang Cao, Yizhe Xue, Jie Pang, Shiyuan Zhou, Peipei Xu, Yonggong Yang, Xiaoping Zhang, Jun Qian and 8 more

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miaoxin PengDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China.
Yueyi XuDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China.
Xuefang CaoMatridx Biotechnology Co., Ltd., Hangzhou, 310000, Zhejiang, People's Republic of China.
Yizhe XueShaan Probiomicros Co., Ltd., Xi'an, 710061, Shanxi, People's Republic of China.
Jie PangDepartment of Hematology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210008, Jiangsu, People's Republic of China.
Shiyuan ZhouDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China.
Peipei XuDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China.
Yonggong YangDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China.
Xiaoping ZhangDepartment of Hematology, Medical School, Zhongda Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, Jiangsu, People's Republic of China.
Jun QianDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People's Republic of China.
Yang WangDepartment of Hematology, Xuzhou Central Hospital, Xuzhou, 221009, Jiangsu, People's Republic of China.
Xuzhang LuDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, 213000, Jiangsu, People's Republic of China.
Yan WanDepartment of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, No.62 Huaihai South Road, Huai'an, 223002, Jiangsu, People's Republic of China.
Yu SunDepartment of Hematology, 2nd Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, People's Republic of China.
Xiaoying HuaDepartment of Hematology, Changzhou First People's Hospital, No.185 Juqian Street, Tianning District, Changzhou, 213003, Jiangsu, China.
Yan XuDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China. 18260090078@163.com.
Bing ChenDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China. chenbing2004@126.com.
Jian OuyangDepartment of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, Jiangsu, People's Republic of China. df21350064@smail.nju.edu.cn.

Funding

Center for Clinical Trials, Japan Medical Association 2022-LCYJ-PY-46Clinical Trials from the Affiliated Drum Tower Hospital 2021-LCYJ-MS-19Jiangsu Provincial Key Research and Development Program BE2023656Nanjing Municipal Health Science and Technology Development Special Fund QNX25036
6 · The paper itself

Abstract

introductionInfection is a common and potentially fatal complication during the treatment of hematological diseases, particularly in the context of chemotherapy-induced immunosuppression. The nonselective use of antibiotic prophylaxis in patients with neutropenia in China has persistently accelerated antimicrobial resistance. Early identification of patients at high risk for infection before clinical symptom onset could enable targeted preventive strategies; however, reliable and biologically informed screening approaches remain limited.

methodsWe developed a prediction model for infection risk stratification in newly diagnosed patients with hematological conditions. Plasma metagenomic next-generation sequencing was performed in a prospective cohort of 230 patients. Among them, 116 patients provided prechemotherapy, non-neutropenic plasma samples (cohort A), and 114 patients provided postchemotherapy, neutropenic samples (cohort B). Microbial community profiles were analyzed, and machine learning approaches were applied to construct classifiers for neutropenia status and subsequent infection risk.

resultsPlasma metagenomic profiling revealed a complex microecological landscape in patients with hematological conditions and identified distinct microbial features associated with neutropenia. A trained random forest classifier successfully distinguished patients without neutropenia from patients with neutropenia, achieving an area under the receiver operating characteristic curve of 0.8324. Importantly, a microorganism-based random forest model was established to predict patients at high risk of infection, yielding an area under the curve of 0.942. Nested cross-validation demonstrated high classification accuracy, correctly identifying 99.1% of patients who subsequently developed infections and 72.7% of patients who remained infection-free. Furthermore, integration of microbial features with clinical metrics improved predictive performance, resulting in an area under the curve of 0.953.

conclusionsThis microorganism-based prediction model provides an effective tool for infection risk stratification in patients with hematological conditions. By enabling early identification of high-risk individuals, the model has potential clinical utility for guiding precise preventive interventions and optimizing infection management strategies, which can significantly reduce the use of prophylactic antibiotics, thereby mitigating the development of resistance. REGISTRATION NUMBER: ChiCTR2100042992.

Indexed as

Hematological diseasesInfectionMetagenomic next-generation sequencing (mNGS)Microecological landscapePredictionRisk stratification

Identifiers

PMID42560632
PMCPMC13570876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.